Monitor for the planned US Phase 3 trial initiation in 2H 2026 and follow-up on the $175M offering details, as these will be key catalysts for the stock. The strong Phase 3 data in China de-risks the acne program.
Price Chart
Executive Summary
Sagimet Biosciences disclosed clinical progress in its acne and MASH programs, including successful Phase 3 results for denifanstat in China and plans for a US Phase 3 trial. The company also announced a $175M stock offering to fund operations through 2028.
Key Facts
- Denifanstat met all primary and secondary endpoints in a Phase 3 trial for moderate to severe acne conducted by partner Ascletis in China
- NDA for denifanstat in acne was accepted by China's NMPA in December 2025
- Sagimet plans to initiate a Phase 3 trial in the US for moderate to severe acne in the second half of 2026
- Company announced a $175M underwritten offering of Series A Common Stock
- Cash position of $104.5M as of March 31, 2026, expected to fund operations through 2028
Financial Impact
$175M stock offering announced, $104.5M cash on hand as of March 31, 2026
Risk Factors
- Dilution from $175M stock offering
- Regulatory risk in US Phase 3 trial
- Dependence on partner Ascletis for China development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-049015 |
| Document: tm2612794d1_8k.htm | 0001104659-26-049015 |
| Document: 0001104659-26-049015-index-headers.html | 0001104659-26-049015 |
| Document: 0001104659-26-049015-index.html | 0001104659-26-049015 |
| Document: 0001104659-26-049015.txt | 0001104659-26-049015 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $9.95 $9.58 | ▼ −3.72% | ▼ −3.20% | $9.56 (−3.92%) |
Oct 7, 2026 19d ago | SC 13G | $8.92 $8.93 | ▲ +0.11% | ▼ −0.49% | $9.56 (+7.17%) |
Oct 1, 2026 25d ago | Press Release | $9.14 $9.03 | ▲ +1.20% | ▲ +1.88% | $9.56 (−4.60%) |
Sep 30, 2026 26d ago | Press Release | $9.88 $9.37 | ▲ +5.16% | ▲ +5.34% | $9.56 (+3.24%) |
Sep 30, 2026 26d ago | 8-K | $9.88 $9.37 | ▼ −5.16% | ▼ −5.34% | $9.56 (−3.24%) |
Sep 22, 2026 4w ago | Institutional Cluster | $11.09 $10.42 | ▼ −6.04% | ▼ −5.32% | $9.56 (−13.80%) |
Aug 25, 2026 8w ago | Press Release | $10.29 $10.86 | ▲ +5.54% | ▲ +5.52% | $9.56 (−7.09%) |
Aug 11, 2026 10w ago | 8-K | $9.52 $9.39 | ▼ −1.37% | ▼ −1.62% | $9.56 (+0.42%) |
Aug 11, 2026 10w ago | Press Release | $9.52 $9.39 | ▼ −1.37% | ▼ −1.62% | $9.56 (+0.42%) |
Jul 22, 2026 13w ago | Insider Cluster | $7.01 $7.07 | ▲ +0.86% | ▲ +0.75% | $9.56 (+36.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers